BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38069368)

  • 1. Z-Ligustilide Combined with Cisplatin Reduces PLPP1-Mediated Phospholipid Synthesis to Impair Cisplatin Resistance in Lung Cancer.
    Geng P; Zhao J; Li Q; Wang X; Qin W; Wang T; Shi X; Liu X; Chen J; Qiu H; Xu G
    Int J Mol Sci; 2023 Dec; 24(23):. PubMed ID: 38069368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ligustilide inhibits the proliferation of non-small cell lung cancer via glycolytic metabolism.
    Jiang X; Zhao W; Zhu F; Wu H; Ding X; Bai J; Zhang X; Qian M
    Toxicol Appl Pharmacol; 2021 Jan; 410():115336. PubMed ID: 33212065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SNHG7 mediates cisplatin-resistance in non-small cell lung cancer by activating PI3K/AKT pathway.
    Chen K; Abuduwufuer A; Zhang H; Luo L; Suotesiyali M; Zou Y
    Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6935-6943. PubMed ID: 31486493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of PI3K/Akt pathway by G protein-coupled receptor 37 promotes resistance to cisplatin-induced apoptosis in non-small cell lung cancer.
    Liu H; Zhu Y; Niu H; Jie J; Hua S; Bai X; Wang S; Song L
    Cancer Med; 2023 Oct; 12(19):19777-19793. PubMed ID: 37732632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nephroprotective effects of ferulic acid, Z-ligustilide and E-ligustilide isolated from Angelica sinensis against cisplatin toxicity in vitro.
    Bunel V; Antoine MH; Nortier J; Duez P; Stévigny C
    Toxicol In Vitro; 2015 Apr; 29(3):458-67. PubMed ID: 25561245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Z-ligustilide restores tamoxifen sensitivity of ERa negative breast cancer cells by reversing MTA1/IFI16/HDACs complex mediated epigenetic repression of ERa.
    Ma H; Li L; Dou G; Wang C; Li J; He H; Wu M; Qi H
    Oncotarget; 2017 Apr; 8(17):29328-29345. PubMed ID: 28415616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. d-Borneol enhances cisplatin sensitivity via p21/p27-mediated S-phase arrest and cell apoptosis in non-small cell lung cancer cells and a murine xenograft model.
    Li J; Yuan J; Li Y; Wang J; Gong D; Xie Q; Ma R; Wang J; Ren M; Lu D; Xu Z
    Cell Mol Biol Lett; 2022 Jul; 27(1):61. PubMed ID: 35883026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LncRNA BC200 regulates the cell proliferation and cisplatin resistance in non-small cell lung cancer via PI3K/AKT pathway.
    Gao BB; Wang SX
    Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1093-1101. PubMed ID: 30779077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-539 enhances chemosensitivity to cisplatin in non-small cell lung cancer by targeting DCLK1.
    Deng H; Qianqian G; Ting J; Aimin Y
    Biomed Pharmacother; 2018 Oct; 106():1072-1081. PubMed ID: 30119173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells.
    Li A; Cao W; Liu X; Zhang Y; Ma Y; Xu R; Zhang R; Liu X; Zhou S; Wang R; Liu J; Tang X
    J Cancer Res Clin Oncol; 2020 Jul; 146(7):1737-1749. PubMed ID: 32342201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long non‑coding RNA AK001796 contributes to cisplatin resistance of non‑small cell lung cancer.
    Liu B; Pan CF; Ma T; Wang J; Yao GL; Wei K; Chen YJ
    Mol Med Rep; 2017 Oct; 16(4):4107-4112. PubMed ID: 29067469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circular RNA hsa_circ_0096157 contributes to cisplatin resistance by proliferation, cell cycle progression, and suppressing apoptosis of non-small-cell lung carcinoma cells.
    Lu H; Xie X; Wang K; Chen Q; Cai S; Liu D; Luo J; Kong J
    Mol Cell Biochem; 2020 Dec; 475(1-2):63-77. PubMed ID: 32767026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitization of tamoxifen-resistant breast cancer cells by Z-ligustilide through inhibiting autophagy and accumulating DNA damages.
    Qi H; Jiang Z; Wang C; Yang Y; Li L; He H; Yu Z
    Oncotarget; 2017 Apr; 8(17):29300-29317. PubMed ID: 28431397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of METTL14-mediated m
    Gong S; Wang S; Shao M
    J Mol Med (Berl); 2022 Dec; 100(12):1771-1785. PubMed ID: 36352154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of vitamin D on malignant behavior of non-small cell lung cancer cells.
    Songyang Y; Song T; Shi Z; Li W; Yang S; Li D
    Gene; 2021 Feb; 768():145309. PubMed ID: 33197518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inactivation of AKT/NF‑κB signaling by eurycomalactone decreases human NSCLC cell viability and improves the chemosensitivity to cisplatin.
    Dukaew N; Chairatvit K; Pitchakarn P; Imsumran A; Karinchai J; Tuntiwechapikul W; Wongnoppavich A
    Oncol Rep; 2020 Oct; 44(4):1441-1454. PubMed ID: 32945500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased ABCC2 expression predicts cisplatin resistance in non-small cell lung cancer.
    Chen Y; Zhou H; Yang S; Su D
    Cell Biochem Funct; 2021 Mar; 39(2):277-286. PubMed ID: 32815556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
    Gao J; Meng Q; Zhao Y; Chen X; Cai L
    BMC Cancer; 2016 Jul; 16():470. PubMed ID: 27411790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevation of FGD5-AS1 contributes to cell progression by improving cisplatin resistance against non-small cell lung cancer cells through regulating miR-140-5p/WEE1 axis.
    Fu J; Cai H; Wu Y; Fang S; Wang D
    Gene; 2020 Sep; 755():144886. PubMed ID: 32534055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TAZ inhibition restores sensitivity of cisplatin via AKT/mTOR signaling in lung adenocarcinoma.
    Xu W; Wei Y; Li Y; Yin Y; Yuan W; Yang Y; Zhao W; Wu J
    Oncol Rep; 2017 Sep; 38(3):1815-1821. PubMed ID: 28737828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.